Literature DB >> 30504059

Electro convulsive therapy: Modification of its effect on the autonomic nervous system using anti-cholinergic drugs.

Søren T Just Christensen1, Jonathan Myrup Staalsø2, Anders Jørgensen3, Pia Weikop4, Niels Vidiendal Olsen5, Martin Balslev Jørgensen6.   

Abstract

The antidepressant efficacy of electroconvulsive therapy (ECT) is correlated to the quality of the seizure as measured by EEG but has also been linked to the magnitude of changes in hemodynamic variables. Muscarinic receptor antagonists are frequently used in the treatment, and are known to affect the hemodynamic response. We hypothesized that atropine and glycopyrrolate alter the hemodynamic and autonomic hormonal response to ECT. In a randomized, cross-over study design 23 patients received either atropine, glycopyrrolate or placebo before ECT. Hemodynamic variable, EEG and EMG, and blood adrenaline, noradrenaline and pancreatic polypeptide was determined. No geriatric patients were included. Hemodynamic changes with ECT can be divided into three phases: Drop in blood pressure and pulse rate in 1st post-stimulus phase was less when using 1 mg atropine. In 2nd post-stimulus phase atropine gave a higher systolic blood pressure. No differences were seen in hormone levels after ECT in the three interventions. A significant longer tonic clonic seizure was seen in the glycopyrrolate group and a tendency of the same was seen with atropine. The study found that the changes in hemodynamic variables induced by ECT can be altered by concomitant administration of muscarinic receptor antagonist.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30504059     DOI: 10.1016/j.psychres.2018.11.035

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  1 in total

1.  Effects of preemptive intravenous paracetamol and ibuprofen on headache and myalgia in patients after electroconvulsive therapy: A placebo-controlled, double-blind, randomized clinical trial.

Authors:  Erol Karaaslan; Sedat Akbas; Ahmet Selim Ozkan; Esra Porgali Zayman
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.